ARVO awards 2024 Carl Camras Translational Research Award


Glenn Yiu, MD, PhD, was chosen for this grant. Yiu is a retinal specialist and clinician-scientist currently a professor of ophthalmology at the University of California, Davis.

Hands holding up a trophy (Image credit: AdobeStock/Shutter2U)

(Image credit: AdobeStock/Shutter2U)

The Association for Research in Vision and Ophthalmology (ARVO) Foundation announced that Glenn Yiu, MD, PhD, has won the 2024 Carl Camras Translational Research Award.

This $12,000 award is granted annually to young investigators working in areas of translational research. The intent of this award is to recognize early-career researchers who show excellence in research, and their fundamental scientific discoveries, concepts and novel technologies have led to or have the promise of leading to clinical application.1

Supported by the ARVO Foundation, this award honors Dr. Carl Camras, who is highly respected for his work as a glaucoma specialist and a research scientist.1

According to the press release1, the 2024 recipient, Yiu is recognized for his work not only as a retinal specialist and clinician-scientist currently a professor of ophthalmology at the University of California, Davis, but also for his innovation.

He leads a translational research program studying age-related macular degeneration (AMD) and other retinal diseases, focusing ocular imaging technologies, gene editing and delivery, and animal models of retinal disease. Yiu reported the first use of CRISPR-based genome editing as a treatment strategy for wet AMD, discovered the use of microneedles for suprachoroidal gene delivery, and pioneered important studies on drusen evolution and other retinal disease models in rhesus monkeys. Yiu also serves as director of tele-ophthalmology at UC Davis, where he has pioneered a teleretinal screening program to expand eye screening among diabetic patients in California.1

In the press release1, Yiu shared what this award means to him, saying, "I am humbled and honored to receive the Carl Camras Translational Research Award. Dr. Camras embodied the ideals of a clinician-scientist who can leverage his knowledge and compassion as a physician to develop novel therapies as a translational researcher. His breakthrough work in prostaglandin analogues and its impact on glaucoma patients worldwide reminds me of the importance of curiosity, perseverance, and empathy in bringing about new treatments and technologies. This award will inspire me to continue making greater impact on the lives of patients with retinal diseases."

1. ARVO Foundation announces winner of 2024 Carl Camras Translational Research Award. The Association for Research in Vision and Ophthalmology (ARVO). Published January 22, 2024. Accessed January 31, 2024.
Related Videos
Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally
ARVO 2024: Study Reveals Faricimab's Potential for Extended Dosing in nAMD
TENAYA, LUCERNE year 2 data reveals promising results for faricimab
How to diagnose geographic atrophy earlier
World Sight Day 2022: Eye care professionals share what global vision means to them
Samsara Vision update: Concerto trial recruiting patients with late-stage AMD
Understanding fluid dynamics in wet macular degeneration
YOSEMITE, RHINE treat-and-extend data show favorable results for faricimab for the treatment of DME
What are you most excited about in the field of retina? Tunde Peto, MD, PhD weighs in
Leveraging noninvasive ophthalmic imaging for patients with Alzheimer disease and analyzing UK Biobank data
© 2024 MJH Life Sciences

All rights reserved.